Literature DB >> 15720981

Surgical treatment of infected aneurysms and pseudoaneurysms of the thoracic and abdominal aorta.

Albert C W Ting1, Stephen W K Cheng, Pei Ho, Jensen T C Poon, James H L Tsu.   

Abstract

BACKGROUND: To review the outcome of infected aneurysms and pseudoaneurysms of the thoracic and abdominal aorta treated in a major teaching hospital.
METHODS: Between December 1994 and January 2003, 13 infected aortic aneurysms and pseudoaneurysms (5 thoracic, 4 paravisceral, 4 infrarenal) in 10 consecutive patients were treated surgically. Aortic debridement with in situ reconstruction is our standard practice. Endovascular repair was offered to suitable patients with thoracic aortic involvement.
RESULTS: There were six men and four women with a mean age of 63 years. The commonest pathogen was Salmonella species, accounting for 50% of the cases. Aortic debridement with in situ revascularization was performed for six patients with visceral reconstruction in four of them. One patient with aortic bifurcation involvement and gross purulent infection had ligation and debridement followed by right axillobifemoral bypass. Four infected thoracic aortic pseudoaneurysms in three other patients underwent endovascular repair. There was no hospital death, limb loss, renal failure, or intestinal ischemia. There were two late deaths from sepsis and pneumonia at 3 months and 77 months after operation. Eight patients were alive after a mean follow-up of 36 months and no late graft infection was evident.
CONCLUSIONS: Surgical treatment for infected aortic aneurysms with in situ reconstruction is associated with favorable outcome and good long-term result. Endovascular repair has a potential role.

Entities:  

Mesh:

Year:  2005        PMID: 15720981     DOI: 10.1016/j.amjsurg.2004.03.020

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  26 in total

1.  Septic rupture of an atherosclerotic plaque of the ascending aorta.

Authors:  Jean Michel Maillet; Tonino Palombi; Jean-Louis Sablayrolles; Nicolas Bonnet
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-22

2.  Mycotic thoracoabdominal aneurysms.

Authors:  Usman Jaffer; Richard Gibbs
Journal:  Ann Cardiothorac Surg       Date:  2012-09

3.  A real mycotic aneurysm-mycotic aneurysm of the abdominal aorta due to fungal infection.

Authors:  Deniz Tihan; Murat Aksoy
Journal:  Ulus Cerrahi Derg       Date:  2014-12-01

4.  Mycotic aneurysm caused by Clostridium septicum in a patient with colorectal cancer.

Authors:  Winesh Ramphal; Niels J Raaijmakers; Marjolein van der Klift; Jan H Wijsman; Jan A J W Kluytmans; Eelco J Veen
Journal:  Infection       Date:  2018-05-29       Impact factor: 3.553

5.  Mycotic aneurysm of the thoracoabdominal aorta in a child with end-stage renal disease.

Authors:  Nicholas D Andersen; Syamal D Bhattacharya; Judson B Williams; Richard L McCann; G Chad Hughes
Journal:  J Vasc Surg       Date:  2011-07-01       Impact factor: 4.268

6.  Primary Infected Aortic Aneurysm: Clinical Presentation, Pathogen, and Outcome.

Authors:  Cheng-Hsin Lin; Ron-Bin Hsu
Journal:  Acta Cardiol Sin       Date:  2014-11       Impact factor: 2.672

7.  Endovascular exclusion of mycotic aortic aneurysm.

Authors:  Thomas J Takach; Peter N Kane; Jeko M Madjarov; Jeremiah H Holleman; Francis Robicsek; Timothy S Roush
Journal:  Tex Heart Inst J       Date:  2007

8.  Successful emergency endovascular treatment of juxtarenal and infrarental mycotic aortic aneurysms in patients with small diameter aortae using Cook(®) Zenith ESLE Stentgrafts.

Authors:  Y C Chan; A C Ting; W K Yiu; S W Cheng
Journal:  World J Emerg Med       Date:  2012

9.  Acute Conditions Caused by Infectious Aortitis.

Authors:  Jiri Molacek; Vladislav Treska; Jan Baxa; Bohuslav Certik; Karel Houdek
Journal:  Aorta (Stamford)       Date:  2014-06-01

Review 10.  [Rare aortic diseases: infections, tumors, congenital anomalies].

Authors:  P Erhart; M Wortmann; C Wieker; B Kovács; M Wehrmeister; D Böckler
Journal:  Chirurg       Date:  2014-09       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.